/AKABY

AKABY Stock - ALK-Abelló A/S

Q: What is the analyst price target for AKABY?

Analyst price target information is not currently available for AKABY.

Q: What is AKABY's market cap?

Market capitalization information is not currently available for AKABY.

Healthcare|Biotechnology|OTC

$90.00+0.00%

+$0.00 (+0.00%) • Apr 24

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $99.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for AKABY

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2017

FY2018

FY2019

FY2020

FY2021

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.43

52W High$104.38

52W Low$31.01

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2021	FY2020	FY2019	FY2018	FY2017
Revenue	$3.92B	$3.49B	$3.27B	$2.92B	$2.91B
Gross Profit	$2.40B	$2.03B	$1.89B	$1.63B	$1.64B
Gross Margin	61.2%	58.1%	57.8%	56.0%	56.4%
Operating Income	$302.00M	$150.00M	$-14,000,000	$-96,000,000	$-80,000,000
Net Income	$219.00M	$25.00M	$-50,000,000	$-170,000,000	$-158,000,000
Net Margin	5.6%	0.7%	-1.5%	-5.8%	-5.4%
EPS	$1.00	$0.11	$-0.23	$-0.78	$-0.80

Company Overview

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.

Visit Website